证券代码：600568 证券简称：ST 中珠 公告编号：2026-006 号 中珠医疗控股股份有限公司 关于下属公司收到民事判决书的公告 一、本次诉讼的基本情况 2017 年 7 月 25 日，被告一国恒建设（承包人）与原告弘洁建设（分包人） 签署了《北京市建设工程施工专业分包合同》，双方约定，鉴于被告一国恒建设 与被告二忠诚肿瘤医院已经签订的《北京忠诚肿瘤医院建筑安装工程施工合同》， 就本机电安装工程分包施工事项订立本合同，并就合同价格、合同价款支付方式、 结算等进行了约定。专业分包合同签署后，原告弘洁建设依约对专业分包合同约 案件所处的诉讼阶段：一审判决 公司下属公司所处的当事人地位：被告 涉案的金额：19,628,631.07 元 是否会对上市公司损益产生负面影响：鉴于本案一审判决尚未生效，上 述案件对公司本期利润或期后利润的影响尚存在不确定性，公司将根据 相关进展情况及时履行信息披露义务。 定的工程进行施工，于 2019 年 7 月 12 日完成施工并竣工。 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 但 ...

Market Overview - The medical services sector experienced a decline of 1.64% on January 28, with Guangzheng Eye Care leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] Individual Stock Performance - Guangzheng Eye Care (002524) saw a significant drop of 8.63%, closing at 5.08, with a trading volume of 1.41 million shares and a transaction value of 721 million [2] - Other notable declines included Yinuosi (688710) down 7.45% and Haoyuan Pharmaceutical (688131) down 6.49% [2] - In contrast, ST Zhongzhu (600568) increased by 1.43%, closing at 2.83, with a trading volume of 338,300 shares [1] Capital Flow Analysis - The medical services sector experienced a net outflow of 1.697 billion in institutional funds, while retail investors saw a net inflow of 1.544 billion [2] - Notable stocks with significant capital inflow included Sunshine Nuohe (688621) with a net inflow of 27.668 million from institutional investors [3] - Conversely, stocks like ST Zhongzhu (600568) and Wanbang Medical (301520) faced net outflows from institutional investors [3]

Group 1 - The Nipah virus outbreak in India has led to increased attention on related concept stocks, with several companies responding urgently to the situation [1] - Companies such as Capbio and Daan Gene have reported significant stock price increases, with Capbio rising by 20% and Daan Gene by 9.99% as of January 27 [2] - Various A-share listed companies are disclosing their technology and product layouts related to Nipah virus testing, including Wanfu Bio and Shengxiang Bio, which have developed specific testing kits [3][4] Group 2 - Capbio has developed a Nipah virus nucleic acid testing kit using fluorescence PCR technology, providing essential support for global quarantine and disease control monitoring [4] - Wanfu Bio has launched different product forms of the Nipah virus nucleic acid testing kit, compatible with its molecular POCT platform and other PCR systems [3] - Some companies, such as Hualan Biological and others, have clarified that they do not have any business related to Nipah virus vaccines or products [5][6]

Core Insights - The launch of the Jinbiao Niu light-flavored liquor represents a strategic choice by Niulanshan, focusing on a deep reconstruction of product-consumer interaction after years of development [1][3] - The product's creation was driven by insights into the preferences of the younger generation, emphasizing a "light flavor" category that redefines the overall flavor profile for a more comfortable drinking experience [3][10] Product Development - The development process involved extensive formula adjustments, numerous taste tests, and meticulous attention to packaging design, akin to crafting a work of art [3][4] - The product was launched without prior marketing hype, relying on organic traffic and initial buyers as "seed users" to build authentic word-of-mouth [4][6] Marketing Strategy - A content resonance plan was initiated to encourage creators in lifestyle and culinary fields to share genuine experiences, leading to organic discussions and increased visibility [6][10] - A product launch event on January 13, 2026, attracted over 2.8 million viewers, marking a significant moment of engagement and response to early curiosity [6][9] Market Performance - Following the launch, the product quickly gained popularity, selling nearly 5,000 boxes within ten days and becoming a trending item on Douyin [9][10] - The majority of purchasers are aged between 20-35, with high rates of repurchase and recommendations, indicating successful alignment with target consumer needs [10][12] Conclusion - The journey from a silent launch to a market explosion demonstrates the effectiveness of a product-driven approach in the contemporary consumer market [12] - The experience reinforces the belief that effective communication stems from confidence in product quality and genuine respect for consumer choices [12]

Core Viewpoint - Zhongzhu Medical Holdings Co., Ltd. expects a net profit loss of 100 million to 150 million yuan for the year, with a loss of 110 million to 160 million yuan after excluding non-recurring gains and losses [1][4]. Group 1: Reasons for Loss - The anticipated loss is primarily due to two factors: the impact of the real estate market environment leading to a decline in property prices, resulting in significant asset impairment losses from commercial assets and substantial bad debt provisions for other receivables from joint ventures in commercial real estate projects [4]. - Additionally, the Beijing Loyal Oncology Hospital project has been unable to operate normally, leading to losses, and the company is currently executing a court ruling for its vacating [5]. Group 2: Company Background - Zhongzhu Medical was listed on the Shanghai Stock Exchange in May 2001, with its main business activities including pharmaceutical manufacturing, medical services, medical devices, and real estate [5]. - Zhongzhu Jun Tian (Beijing) Medical Technology Co., Ltd. is a subsidiary of Zhongzhu Medical and is the parent company of Beijing Loyal Oncology Hospital, which has been in a state of pending operation due to disputes over lease contracts and construction contracts since October 2022 [5].

Core Viewpoint - Company ST Zhongzhu (600568) expects a net loss attributable to shareholders of 1 billion to 1.5 billion yuan for the year 2025, an improvement from a loss of 6.2 billion yuan in the previous year [4] Financial Performance - The forecasted net profit loss for 2025 is between 1 billion and 1.5 billion yuan, while the non-recurring net profit loss is expected to be between 1.1 billion and 1.6 billion yuan, compared to a loss of 6.24 billion yuan in the previous year [4] - Historical net profit and non-recurring net profit figures show a consistent decline, with the company reporting a net loss of 6.2 billion yuan in 2023 and 7.99 billion yuan in 2022 [15] - The company's price-to-book ratio (LF) is approximately 3.16 times, and the price-to-sales ratio (TTM) is about 9.5 times based on the latest closing price [4] Business Operations - The company's main business areas include pharmaceutical manufacturing, medical services, medical devices, and real estate [14] - The decline in performance is attributed to the impact of the real estate market environment, leading to a decrease in property prices and significant asset impairment losses from commercial assets [14] - The Beijing Loyal Oncology Hospital project has incurred losses due to its inability to operate normally, and the company is currently executing a court ruling for its vacating [14]

特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）持股 5%以 上股东广州云鹰资本管理有限公司（以下简称"云鹰资本"）、持股 5%以上股东郑 子贤，于 2025 年 11 月 11 日分别与共青城梅花腾龙起飞投资合伙企业（有限合伙） （以下简称"梅花投资"）签署《关于中珠医疗控股股份有限公司之股份转让协议》。 云鹰资本与郑子贤将其持有的合计 206,821,844 股公司股份（占公司总股本的 10.38%），以人民币 1.95 元/股的价格，通过协议转让方式转让给梅花投资。本次股 份过户完成后，梅花投资持有公司 206,821,844 股股份，占公司总股本的 10.38%， 成为公司持股 5%以上股东；云鹰资本、郑子贤不再持有公司股份。 本次协议转让事项已通过上海证券交易所合规性确认，并于 2026 年 1 月 23 日取得中国证券登记结算有限责任公司出具的《证券过户登记确认书》，过户日期为 2026 年 1 月 22 日，过户数量为 20 ...

Core Viewpoint - ST Zhongzhu (600568.SH) expects to reduce its losses in 2025, projecting a net profit attributable to shareholders of the listed company between -100 million yuan and -150 million yuan, compared to the previous year [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -110 million yuan and -160 million yuan for the year 2025 [1]

Financial Performance Expectations - The company expects a net profit attributable to shareholders for 2025 to be between -100 million and -150 million yuan[3]. - The expected net profit attributable to shareholders after deducting non-recurring gains and losses for 2025 is projected to be between -110 million and -160 million yuan[5]. - The estimated net profit for 2025 represents a reduction in losses compared to the previous year[5]. Previous Year Financial Results - In 2024, the total profit was -627.30 million yuan, with a net profit attributable to shareholders of -620.22 million yuan[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses in 2024 was -623.87 million yuan[7]. - The company reported a loss per share of -0.3148 yuan for the previous year[8]. Reasons for Expected Losses - The primary reasons for the expected losses include asset impairment losses due to declining real estate prices and significant bad debt provisions from joint ventures[9]. - The Beijing Loyal Oncology Hospital project is incurring losses and is undergoing court-ordered vacating[10]. Financial Data and Auditing - The financial data provided is preliminary and has not been audited by registered accountants[11]. - Investors are advised to exercise caution as the final audited financial data will be disclosed in the official 2025 annual report[12].

Core Viewpoint - ST Zhongzhu announced a preliminary estimate of a net loss attributable to shareholders for 2025 ranging from -100 million to -150 million yuan, indicating an improvement compared to the previous year's loss of -620.22 million yuan [1] Financial Performance - The expected non-recurring net profit for 2025 is estimated to be between -110 million and -160 million yuan, compared to -623.87 million yuan in the same period last year [1] - The company is experiencing a reduction in losses year-on-year, reflecting a decrease in the scale of financial distress [1] Reasons for Performance - The primary reasons for the anticipated losses include the impact of the real estate market, significant impairment of commercial assets, and substantial bad debt losses [1] - Additionally, the Beijing Loyal Oncology Hospital project has incurred losses and is being vacated, contributing to the overall financial strain [1]